23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Dianthus Therapeutics, Inc. › 2025-2026

Dianthus Therapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Dianthus Therapeutics, Inc.’s Form 8-K, filed May 22, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 266Asset managers, any item
  • 1,679Fund votes
  • May 21, 2026Meeting date

Results at a glance

Meeting of May 21, 2026: 5 items on Dianthus Therapeutics, Inc.’s Form 8-K, filed May 22, 2026: 2 approved · 3 passed (calculated).

Dissent

Notable dissent: 1 director (19.4% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Dianthus Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Dianthus Therapeutics, Inc.

These tallies are Dianthus Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 22, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Dianthus Therapeutics, Inc. — official shareholder meeting results, meeting held May 21, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Sujay Kango 42,739,315---- 479,1993,585,554 99%Passed (calculated)—
Elect Director: Anne McGeorge 34,814,377---- 8,404,1373,585,554 81%Passed (calculated)—
Elect Director: Jonathan Violin, Ph.D 42,799,946---- 418,5683,585,554 99.0%Passed (calculated)—
2. Advisory Vote on Executive Compensation 41,004,5071,713,043500,964 --3,585,554 96%Approved—
3. Ratification of Appointment of Independent Registered Public Accounting Firm 46,298,3195,279500,471 ---- 99.9%Approved—

Source: Dianthus Therapeutics, Inc., Form 8-K, filed with the SEC on May 22, 2026 — read the filing on EDGAR.

How asset managers voted at the Dianthus Therapeutics, Inc. 2025-2026 meeting

266 asset managers disclosed a vote on at least one Dianthus Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Anne McGeorge

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD
FOR: 34,814,377WITHHELD: 8,404,137
Details: description as filed, official tally, votes by 83 asset managers

Description as filed by funds: To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Anne McGeorge

Dianthus Therapeutics, Inc.’s own tally for this item (“Elect Director: Anne McGeorge”): 34,814,377 for, 8,404,137 withheld, per its Form 8-K filed May 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 83 asset managers below reported 12,685,923 for, 3,385,471 withheld, 11 abstained.

FORWITHHOLD
FOR: 12,685,923ABSTAIN: 11WITHHOLD: 3,385,471
Largest asset managers voting on “To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders ” at Dianthus Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity4,800,1920 00For
Vanguard3,807,0550 114,662For
T. Rowe Price828,8920 0854,698Mixed
BlackRock800,3330 00For
ALGER INSTITUTIONAL FUNDS00 0488,463Withhold
FRANKLIN STRATEGIC SERIES00 0466,784Withhold
State Street423,1230 01,134For
Charles Schwab305,8830 00For
AllianceBernstein00 0288,417Withhold
ALGER FUNDS II00 0230,381Withhold
MUTUAL FUND SERIES TRUST225,2610 00For
Columbia Threadneedle220,1880 00For
Prudential/PGIM193,8880 016,128Mixed
AB DISCOVERY GROWTH FUND, INC.00 0203,248Withhold
TIAA196,5170 00For
Equitable89,3320 099,924Mixed
ALGER FUNDS00 0156,341Withhold
Dimensional00 0110,894Withhold
Invesco90,1390 00For
Hartford79,2190 00For
American Century00 078,532Withhold
Lord Abbett71,6350 00For
Principal00 065,125Withhold
Russell Investments63,6440 00For
QUANTITATIVE MASTER SERIES LLC58,2660 00For

Showing the 25 largest of 83 asset managers. All 83 are in the interactive database (link above).

Elect Director: Jonathan Violin, Ph.D

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

99.0% Majority: yes · of votes cast

FOR 99.0%
FOR: 42,799,946WITHHELD: 418,568
Details: description as filed, official tally, votes by 83 asset managers

Description as filed by funds: To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Jonathan Violin, Ph.D.

Dianthus Therapeutics, Inc.’s own tally for this item (“Elect Director: Jonathan Violin, Ph.D”): 42,799,946 for, 418,568 withheld, per its Form 8-K filed May 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.0% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 83 asset managers below reported 15,934,925 for, 136,480 withheld.

FOR
FOR: 15,934,925WITHHOLD: 136,480
Largest asset managers voting on “To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders ” at Dianthus Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity4,800,1920 00For
Vanguard3,808,5630 03,165For
T. Rowe Price1,683,5900 00For
BlackRock800,3330 00For
ALGER INSTITUTIONAL FUNDS488,4630 00For
FRANKLIN STRATEGIC SERIES466,7840 00For
State Street423,6490 0608For
Charles Schwab305,8830 00For
AllianceBernstein288,4170 00For
ALGER FUNDS II230,3810 00For
MUTUAL FUND SERIES TRUST225,2610 00For
Columbia Threadneedle220,1880 00For
Prudential/PGIM209,6820 0334For
AB DISCOVERY GROWTH FUND, INC.203,2480 00For
TIAA196,5170 00For
Equitable189,2560 00For
ALGER FUNDS156,3410 00For
Dimensional00 0110,894Withhold
Invesco90,1390 00For
Hartford79,2190 00For
American Century78,5320 00For
Lord Abbett71,6350 00For
Principal65,1250 00For
Russell Investments63,6440 00For
QUANTITATIVE MASTER SERIES LLC58,2660 00For

Showing the 25 largest of 83 asset managers. All 83 are in the interactive database (link above).

Elect Director: Sujay Kango

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 42,739,315WITHHELD: 479,199
Details: description as filed, official tally, votes by 83 asset managers

Description as filed by funds: To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Sujay Kango

Dianthus Therapeutics, Inc.’s own tally for this item (“Elect Director: Sujay Kango”): 42,739,315 for, 479,199 withheld, per its Form 8-K filed May 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 83 asset managers below reported 15,938,903 for, 132,501 withheld, 1 abstained.

FOR
FOR: 15,938,903ABSTAIN: 1WITHHOLD: 132,501
Largest asset managers voting on “To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders ” at Dianthus Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity4,800,1920 00For
Vanguard3,811,7270 10For
T. Rowe Price1,683,5900 00For
BlackRock800,3330 00For
ALGER INSTITUTIONAL FUNDS488,4630 00For
FRANKLIN STRATEGIC SERIES466,7840 00For
State Street424,2570 00For
Charles Schwab305,8830 00For
AllianceBernstein288,4170 00For
ALGER FUNDS II230,3810 00For
MUTUAL FUND SERIES TRUST225,2610 00For
Columbia Threadneedle220,1880 00For
Prudential/PGIM209,6820 0334For
AB DISCOVERY GROWTH FUND, INC.203,2480 00For
TIAA196,5170 00For
Equitable189,2560 00For
ALGER FUNDS156,3410 00For
Dimensional00 0110,894Withhold
Invesco90,1390 00For
Hartford79,2190 00For
American Century78,5320 00For
Lord Abbett71,6350 00For
Principal65,1250 00For
Russell Investments63,6440 00For
QUANTITATIVE MASTER SERIES LLC58,2660 00For

Showing the 25 largest of 83 asset managers. All 83 are in the interactive database (link above).

Advisory Vote on Executive Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 41,004,507AGAINST: 1,713,043

Prior year: 85.7% for (May 22, 2025 meeting) ▲ 10.3 pts

Details: description as filed, official tally, votes by 266 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation paid to our named executive officers; and

Dianthus Therapeutics, Inc.’s own tally for this item (“2. Advisory Vote on Executive Compensation”): 41,004,507 for, 1,713,043 against — passed, per its Form 8-K filed May 22, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 83 asset managers voting on “To approve, on an advisory basis, the compensation paid to our named executive officers; and” at Dianthus Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity4,800,1920 00For
Vanguard3,811,7253 10For
T. Rowe Price1,683,5900 00For
BlackRock800,3330 00For
ALGER INSTITUTIONAL FUNDS0488,463 00Against
FRANKLIN STRATEGIC SERIES466,7840 00For
State Street424,089168 00For
Charles Schwab305,8830 00For
AllianceBernstein288,4170 00For
ALGER FUNDS II0230,381 00Against
MUTUAL FUND SERIES TRUST225,2610 00For
Columbia Threadneedle220,1880 00For
Prudential/PGIM210,0160 00For
AB DISCOVERY GROWTH FUND, INC.203,2480 00For
TIAA196,5170 00For
Equitable189,2560 00For
ALGER FUNDS0156,341 00Against
Dimensional110,8940 00For
Invesco090,139 00Against
Hartford79,2190 00For
American Century078,532 00Against
Lord Abbett71,6350 00For
Principal65,1250 00For
Russell Investments63,6440 00For
QUANTITATIVE MASTER SERIES LLC58,2660 00For

Fund voting reports, all 83 managers: 14,967,362 for, 1,089,765 against, 14,279 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 205 asset managers voting on “To approve, on an advisory basis, the compensation paid to our named executive officers; and” at Dianthus Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,285,4830 00For
RA CAPITAL MANAGEMENT, L.P.2,611,7330 00For
Fairmount Funds Management LLC2,537,1910 00For
T. Rowe Price2,282,2950 00For
Wellington2,136,2750 00For
Octagon Capital Advisors LP2,086,6670 00For
Polar Capital Holdings Plc1,900,0000 00For
BlackRock1,352,6522,838 00For
Venrock Adviser, LLC1,180,0000 00For
FRED ALGER MANAGEMENT, LLC55,8731,097,202 00Against
FRANKLIN ADVISERS INC955,1050 00For
State Street943,2621,264 00For
AllianceBernstein889,8290 00For
GEODE CAPITAL MANAGEMENT, LLC736,5900 00For
Catalio Capital Management, LP00 482,0000Abstain
Logos Global Management LP475,0000 00For
Citadel469,8010 00For
FARALLON CAPITAL MANAGEMENT, L.L.C.456,7110 00For
SILVERARC CAPITAL MANAGEMENT, LLC427,3940 00For
BRAIDWELL LP404,3250 00For
Cormorant Asset Management, LP393,1510 00For
Bain Capital Life Sciences Investors, LLC362,4700 00For
Vivo Capital, LLC353,9980 00For
JENNISON ASSOCIATES LLC339,2070 00For
Artisan332,1710 00For

Institutional-manager reports, all 205 managers: 34,990,830 for, 1,566,930 against, 497,652 abstained, 1,622 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 46,298,319AGAINST: 5,279

Prior year: 100.0% for (May 22, 2025 meeting) unchanged

Details: description as filed, official tally, votes by 83 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE, LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Dianthus Therapeutics, Inc.’s own tally for this item (“3. Ratification of Appointment of Independent Registered Public Accounting Firm”): 46,298,319 for, 5,279 against — passed, per its Form 8-K filed May 22, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Deloitte & Touche, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 83 asset managers below reported 16,057,126 for, 14,279 abstained.

FOR
FOR: 16,057,126ABSTAIN: 14,279
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE, LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR T” at Dianthus Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity4,800,1920 00For
Vanguard3,811,7270 10For
T. Rowe Price1,683,5900 00For
BlackRock800,3330 00For
ALGER INSTITUTIONAL FUNDS488,4630 00For
FRANKLIN STRATEGIC SERIES466,7840 00For
State Street424,2570 00For
Charles Schwab305,8830 00For
AllianceBernstein288,4170 00For
ALGER FUNDS II230,3810 00For
MUTUAL FUND SERIES TRUST225,2610 00For
Columbia Threadneedle220,1880 00For
Prudential/PGIM210,0160 00For
AB DISCOVERY GROWTH FUND, INC.203,2480 00For
TIAA196,5170 00For
Equitable189,2560 00For
ALGER FUNDS156,3410 00For
Dimensional110,8940 00For
Invesco90,1390 00For
Hartford79,2190 00For
American Century78,5320 00For
Lord Abbett71,6350 00For
Principal65,1250 00For
Russell Investments63,6440 00For
QUANTITATIVE MASTER SERIES LLC58,2660 00For

Showing the 25 largest of 83 asset managers. All 83 are in the interactive database (link above).

Largest Dianthus Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 54,582,749 shares outstanding at the time of that meeting.

Fund voting reports: top Dianthus Therapeutics, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation paid to our named executive officers; and”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 8.79%
2Vanguard 6.98%
3T. Rowe Price 3.08%
4BlackRock 1.47%
5ALGER INSTITUTIONAL FUNDS 0.89%
6FRANKLIN STRATEGIC SERIES 0.86%
7State Street 0.78%
8Charles Schwab 0.56%
9AllianceBernstein 0.53%
10ALGER FUNDS II 0.42%
Institutional-manager reports: top Dianthus Therapeutics, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation paid to our named executive officers; and”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 11.52%
2RA CAPITAL MANAGEMENT, L.P. 4.78%
3Fairmount Funds Management LLC 4.65%
4T. Rowe Price 4.18%
5Wellington 3.91%
6Octagon Capital Advisors LP 3.82%
7Polar Capital Holdings Plc 3.48%
8BlackRock 2.48%
9Venrock Adviser, LLC 2.16%
10FRED ALGER MANAGEMENT, LLC 2.11%

Reported Dianthus Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Dianthus Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
FMR (Fidelity)7,767,686 14.23%Form 13F, quarter ended March 31, 2026
BlackRock3,175,703 5.82%Form 13F, quarter ended March 31, 2026
RA Capital Management, L.P.2,611,733 4.78%Schedule 13G, filed May 15, 2026
Wellington Management2,595,783 4.76%Form 13F, quarter ended March 31, 2026
Vanguard Group2,048,452 3.75%Form 13F, quarter ended March 31, 2026
Citadel Advisors1,648,983 3.02%Form 13F, quarter ended March 31, 2026
State Street1,398,913 2.56%Form 13F, quarter ended March 31, 2026
T. Rowe Price1,146,948 2.10%Form 13F, quarter ended March 31, 2026
Franklin Templeton968,182 1.77%Form 13F, quarter ended March 31, 2026
Geode Capital916,211 1.68%Form 13F, quarter ended March 31, 2026

Percentages above are of 54,582,749 shares outstanding, as reported by Dianthus Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Dianthus Therapeutics, Inc.'s shareholder meeting held May 21, 2026, in the 2025-2026 proxy season, 266 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,679 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation paid to our named executive officers; and — Dianthus Therapeutics, Inc.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Dianthus Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 22, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Dianthus Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Dianthus Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Dianthus Therapeutics (DNTH) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/dianthus-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.